Bilineal acute myeloid leukemia

Summary

Bilineal acute myeloid leukemia (MONDO:0011118) is a cancer and 5 clinical trials. Top therapeutic interventions include enasidenib, clofarabine, and idarubicin. A subtype of acute leukemia of ambiguous lineage — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bilineal acute myeloid leukemia
Mondo ID	MONDO:0011118
Orphanet	98836
NCIT	C6923
UMLS	C0349680
MedGen	87614
GARD	0024773
Is cancer (heuristic)	yes

Also known as: acute bilineal leukaemia · acute bilineal leukemia · bilineal acute leukaemia

Disease family

This is a subtype of acute leukemia of ambiguous lineage. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › myeloid leukemia › acute myeloid leukemia › acute leukemia of ambiguous lineage › bilineal acute myeloid leukemia

Related subtypes (2): acute undifferentiated leukemia, mixed phenotype acute leukemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03683433	PHASE2	RECRUITING	Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
NCT04128501	PHASE2	ACTIVE_NOT_RECRUITING	Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
NCT02135874	PHASE2	COMPLETED	Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
NCT02397720	PHASE2	COMPLETED	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
NCT03807063	PHASE1	WITHDRAWN	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENASIDENIB	4	2
CLOFARABINE	4	1
IDARUBICIN	4	1
SORAFENIB	4	1
VENETOCLAX	4	1
RIMIDUCID	2	1
RIVOGENLECLEUCEL	2	1
CHEMBL3970001	0	1